Welcome to Sequence Card of Peptide


Details of CancerPDF entry with Sequence VGFYESDVMGR
Primary information
sequence IDSeq_8969
Peptide sequenceVGFYESDVMGR
CancerPDF_ID CancerPDF_ID1944, CancerPDF_ID1953, CancerPDF_ID9522, CancerPDF_ID9523,
PMID21136997,21136997,21533267,21533267
Protein NameAlpha-2-macroglobulin,Alpha-2-macroglobulin,Alpha-2-macroglobulin,Alpha-2-macroglobulin
UniprotKB Entry NameA2MG_HUMAN,A2MG_HUMAN,A2MG_HUMAN,A2MG_HUMAN
FluidSerum,Serum,Serum,Serum
M/Z1258.56522,1274.56014,630.28,638.28
Charge1,1,2,2
Mass (in Da)NA,NA,NA,NA
fdrNA,NA,NA,NA
Profiling TechniqueLC-MS,LC-MS,LC-MS,LC-MS
Peptide Identification techniqueLC-MS-MS/MS,LC-MS-MS/MS,LC/MS/MS,LC/MS/MS
Quantification TechniqueLC-ESI-MS,LC-ESI-MS,Multiple Reaction Monitoring,Multiple Reaction Monitoring
Labelled/Label FreeLabel Free,Label Free,Label Free,Label Free
FDRNA,NA,1.49,1.49
CancerPDF_ID CancerPDF_ID1944, CancerPDF_ID1953, CancerPDF_ID9522, CancerPDF_ID9523,
p-ValueNA,NA,NA,NA
SoftwareMASCOT(v. 2.2.01),MASCOT(v. 2.2.01),MASCOT,MASCOT
Length11,11,11,11
Cancer TypeColorectal cancer,Colorectal cancer,Lung adenocarcinoma,Lung adenocarcinoma
DatabaseSwissProt Database,SwissProt Database,Swissprot Database (57.4),Swissprot Database (57.4)
ModificationNA,Oxidation of Met,NA,Oxidation
Number of Patients30 patients and 30 healthy controls,30 patients and 30 healthy controls,62 lung adenocarcinoma and 30 healthy control,62 lung adenocarcinoma and 30 healthy control
RegulationNA,NA,"Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal","Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal"
ValidationLeave One out Cross validation,Leave One out Cross validation,MRM-based validation of 19 candidates,MRM-based validation of 19 candidates
SensitivityNA,NA,NA,NA
SpecificityNA,NA,NA,NA
AccuracyNA,NA,NA,NA
Peptide AtlasPeptideAtlas
IEDB